AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
BUSINESS BRIEFS.(TO THE POINT)
TELECOM
Verizon, unions in contract talks
The local phone giant's workers did not strike Monday as unions agreed to negotiate with Verizon Communications past a weekend deadline, citing "significant progress." The two sides met Sunday for 14 hours to resolve issues like health care costs, job security and transfers to lower-cost regions. They met again Monday. Verizon rose 5%.
MEDICAL
Mylan's Prilosec news hits rivals
Andrx fell 10% and Pharmaceutical Resources 6% after Mylan Labs said it's selling the heartburn and ulcer drug Prilosec. Andrx and Pharmaceutical get royalties from sales of the generic. Other generic drug makers have waited on selling Prilosec until a court rules on some AstraZeneca patents. Mylan, which risks big damages, rose 2%.
CV Therapeutics slumps on delay
- CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for...
- Press release article from: PR Newswire April 15, 2008 700+ words
...15 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that TPG-Axon Capital has agreed to pay CV Therapeutics up to $185 million in exchange for rights to 50 percent of CV Therapeutics' royalty on North American sales...
- CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal.
- Press release article from: PR Newswire February 20, 2009 700+ words
...20 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. today announced that its board...from Astellas Pharma Inc. to acquire CV Therapeutics at a price of $16.00 per share...financial and legal advisors, the CV Therapeutics board concluded that the Astellas...
- CV Therapeutics and Quintiles Modify Ranexa(TM) Sales and Marketing Agreement.
- Press release article from: PR Newswire July 10, 2003 700+ words
CV Therapeutics, Inc. and Quintiles Transnational...The modified agreement provides CV Therapeutics with complete commercialization...range of pharmaceutical services for CV Therapeutics. Under the modified agreement...
- CV Therapeutics Statement on Unsolicited Proposal From Astellas.
- Press release article from: PR Newswire January 28, 2009 700+ words
...recently by Astellas Pharma Inc., CV Therapeutics, Inc. confirmed that it had received...unsolicited proposal by Astellas to acquire CV Therapeutics at a price of $16.00 per share...financial and legal advisors, the CV Therapeutics board of directors had, on November...
- Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash.
- Press release article from: Business Wire January 27, 2009 700+ words
Proposal Values CV Therapeutics at $1.0 Billion and Represents a 41% Premium for CV Therapeutics Stockholders TOKYO -- Astellas Pharma...proposal to the Board of Directors of CV Therapeutics, Inc. (Nasdaq: CVTX) to acquire...
- PTC Therapeutics and CV Therapeutics Announce Collaboration and License...
- Press release article from: PR Newswire June 12, 2006 700+ words
...PTC Therapeutics, Inc. and CV Therapeutics, Inc. announced today that they...Pursuant to the collaboration, PTC and CV Therapeutics will jointly select five targets...collaboration and license agreement, CV Therapeutics will make an initial payment to PTC...
- CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for...
- Press release article from: PR Newswire February 4, 2008 700+ words
...4 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. and Medlogics Device Corporation...under which Medlogics has licensed CV Therapeutics' proprietary biopolymer stent coating...develop a drug eluting stent (DES). CV Therapeutics received Medlogics stock and is entitled...
- Astellas Pharma Issues Statement Regarding CV Therapeutics Rejection of...
- Press release article from: Business Wire February 23, 2009 700+ words
...to its Proposal to Acquire CV Therapeutics TOKYO -- Astellas Pharma Inc...Astellas") today commented on CV Therapeutics, Inc's. (Nasdaq: CVTX...Astellas' proposal to acquire CV Therapeutics for $16 per share in cash...
- CV Therapeutics Appoints Lewis Stuart as Vice President, Sales.
- Press release article from: PR Newswire July 10, 2003 700+ words
CV Therapeutics, Inc. announced today the appointment of Lewis...Ranexa(TM) (ranolazine) and other potential CV Therapeutics products. Mr. Stuart joins CV Therapeutics with more than 20 years of sales and marketing experience...
- CV Therapeutics Advises Stockholders to Take No Action at This Time in Response...
- Press release article from: PR Newswire February 27, 2009 700+ words
...27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. today advised its stockholders...all outstanding common shares of CV Therapeutics at a price of $16.00 per share in cash. CV Therapeutics' board of directors, in consultation...